Full Text View
Tabular View
No Study Results Posted
Related Studies
Pediatric Epilepsy Trial in Subjects 1-24 Months
This study has been completed.
First Received: August 14, 2002   Last Updated: May 15, 2009   History of Changes
Sponsor: GlaxoSmithKline
Information provided by: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00043875
  Purpose

This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures. The medication used in this study has been approved by FDA for the adjunctive treatment of partial seizures in patients 2 years and older.


Condition Intervention Phase
Epilepsy
 Drug: lamotrigine
 Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study
Official Title: A Double-Blind, Placebo-Controlled, Add-on Clinical Trial of the Safety, Pharmacokinetics and Efficacy of LAMICTAL in Pediatric Age Subjects (1-24 Months)

Resource links provided by NLM:

Genetics Home Reference related topics: pyridoxal 5'-phosphate-dependent epilepsy pyridoxine-dependent epilepsy
MedlinePlus related topics: Epilepsy Seizures
Drug Information available for: Lamotrigine
U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • The efficacy of LAMICTAL add-on therapy will be measured by the proportion of subjects who meet escape criteria during the Double-Blind Phase. [ Time Frame: 36 Months ]

Secondary Outcome Measures:
  • Time to escape patterns in Double-Blind phase. Reduction in partial seizure frequency at end of Open-Label Phase. Investigators' global evaluation of subjects' status at end of Open-Label and Double-Blind Phases; Standard pharmacokinetics; Adverse Events [ Time Frame: 36 Months ]

Enrollment: 250
Study Start Date: May 2000
  Eligibility

Ages Eligible for Study:   1 Month to 24 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  • Have a confident diagnosis of epilepsy
  • Must be experiencing 4 or more reliably detectable partial seizures per month while receiving at least 1 anti-epileptic drug (AED)
  • Must weigh at least 7 lbs if currently receiving enzyme inducing antiepileptic drugs (EIADs) OR weigh at least 15 lbs if currently receiving non-enzyme inducing antiepileptic drugs (non-EIADs)
  • Have no underlying chronic metabolism problems
  • Have normal lab results
  • Have a normal electrocardiogram (ECG)

EXCLUSION CRITERIA:

  • Have a diagnosis of severe, progressive myoclonus.
  • Have seizures not related to epilepsy.
  • Have previously demonstrated sensitivity or allergic reaction to the study drug or its related compounds.
  • Have progressive or unstable condition of the nervous system.
  • Used experimental medication within 30 of enrollment into the study.
  • Have any significant, chronic heart, kidney, liver or stomach/intestinal (GI) condition.
  • Current use of the medication felbamate.
  • Current use of adrenocorticotrophic hormone (ACTH).
  • Following a ketogenic diet.
  • Receiving vagal nerve stimulation (VNS).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00043875

  Hide Study Locations
Locations
United States, Arizona
GSK Investigational Site
Tucson, Arizona, United States, 85712
United States, Arkansas
GSK Investigational Site
Little Rock, Arkansas, United States, 72202
United States, California
GSK Investigational Site
Stanford, California, United States, 94305-5235
GSK Investigational Site
Los Angeles, California, United States, 90027
GSK Investigational Site
Los Angeles, California, United States, 90095
United States, Colorado
GSK Investigational Site
Denver, Colorado, United States, 80218
United States, District of Columbia
GSK Investigational Site
Washington, District of Columbia, United States, 20010
United States, Florida
GSK Investigational Site
Tampa, Florida, United States, 33607-6350
GSK Investigational Site
Jacksonville, Florida, United States, 32207
GSK Investigational Site
Tallahassee, Florida, United States, 32308
GSK Investigational Site
Miami, Florida, United States, 33155-3009
GSK Investigational Site
Orlando, Florida, United States, 32835
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30342
GSK Investigational Site
Augusta, Georgia, United States, 30912
United States, Kentucky
GSK Investigational Site
Lexington, Kentucky, United States, 40536-0284
United States, Minnesota
GSK Investigational Site
St. Paul, Minnesota, United States, 55102-2383
United States, Missouri
GSK Investigational Site
Kansas City, Missouri, United States, 64108
United States, New Jersey
GSK Investigational Site
Cherry Hill, New Jersey, United States, 8034
United States, New York
GSK Investigational Site
Syracuse, New York, United States, 13210
United States, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599
GSK Investigational Site
Raleigh, North Carolina, United States, 27607
United States, Ohio
GSK Investigational Site
Akron, Ohio, United States, 44308-1062
GSK Investigational Site
Cleveland, Ohio, United States, 44106
GSK Investigational Site
Columbus, Ohio, United States, 43205
United States, Oregon
GSK Investigational Site
Portland, Oregon, United States, 97239
United States, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213-2583
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75230
GSK Investigational Site
Houston, Texas, United States, 77030
GSK Investigational Site
Fort Worth, Texas, United States, 76104
United States, Virginia
GSK Investigational Site
Richmond, Virginia, United States, 23298
GSK Investigational Site
Charlottesville, Virginia, United States, 22908
GSK Investigational Site
Norfolk, Virginia, United States, 23510
Australia, Queensland
GSK Investigational Site
South Brisbane, Queensland, Australia, 4101
Australia, Victoria
GSK Investigational Site
Parkville, Melbourne, Victoria, Australia, 3050
GSK Investigational Site
West Heidleberg, Melbourne, Victoria, Australia
Australia, Western Australia
GSK Investigational Site
Perth, Western Australia, Australia
Estonia
GSK Investigational Site
Tartu, Estonia, 51014
GSK Investigational Site
Tallinn, Estonia, 13419
France
GSK Investigational Site
Reims Cedex, France, 51092
Hungary
GSK Investigational Site
Szeged, Hungary, 6720
GSK Investigational Site
Debrecen, Hungary, 4012
GSK Investigational Site
Budapest, Hungary, 1094
GSK Investigational Site
Miskolc, Hungary, 3526
Italy, Campania
GSK Investigational Site
Napoli, Campania, Italy, 80131
Italy, Emilia-Romagna
GSK Investigational Site
Bologna, Emilia-Romagna, Italy, 40138
Italy, Lombardia
GSK Investigational Site
Milano, Lombardia, Italy, 20133
GSK Investigational Site
Mantova, Lombardia, Italy, 46100
Italy, Sicilia
GSK Investigational Site
Messina, Sicilia, Italy, 98125
Italy, Veneto
GSK Investigational Site
Padova, Veneto, Italy, 35128
Latvia
GSK Investigational Site
Riga, Latvia, LV 1004
Lebanon
GSK Investigational Site
Beirut, Lebanon, 11072020
Lithuania
GSK Investigational Site
Kaunas, Lithuania, LT-50009
Netherlands
GSK Investigational Site
ROTTERDAM, Netherlands, 3015 GD
GSK Investigational Site
GRONINGEN, Netherlands, 9713 GZ
GSK Investigational Site
UTRECHT, Netherlands, 3584 EA
Portugal
GSK Investigational Site
Lisboa, Portugal, 1150
GSK Investigational Site
Coimbra, Portugal, 3000-075
GSK Investigational Site
Porto, Portugal, 4099-001
Slovakia
GSK Investigational Site
Bratislava, Slovakia, 833 40
GSK Investigational Site
Banska Bystrica, Slovakia, 975 17
GSK Investigational Site
Presov, Slovakia, 080 01
Spain
GSK Investigational Site
Las Palmas De Gran Canaria, Spain, 35016
Turkey
GSK Investigational Site
Ankara, Turkey
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GSK ( Study Director )
Study ID Numbers: LAM20006
Study First Received: August 14, 2002
Last Updated: May 15, 2009
ClinicalTrials.gov Identifier: NCT00043875     History of Changes
Health Authority: United States: Food and Drug Administration;   Lithuania: State Medicine Control Agency - Ministry of Health

Keywords provided by GlaxoSmithKline:
epilepsy
partial seizures
pediatric

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Nervous System Diseases
Central Nervous System Diseases
Calcium Channel Blockers
Cardiovascular Agents
Brain Diseases
Pharmacologic Actions
 Membrane Transport Modulators
Epilepsy
Therapeutic Uses
Lamotrigine
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on November 27, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services